Potent Lp(a) Lowering Following Evolocumab Is Associated With Reduction in Arterial Wall Inflammation

This randomized controlled trial enrolled 129 patients with elevated Lp(a) (≥150 nmol/L) and either clinically manifest cardiovascular disease or high-risk features to receive evolocumab or placebo for 16 weeks, with serial 18F-FDG PET/CT imaging of aortic and carotid arterial wall inflammation as the primary outcome.

Evolocumab reduced LDL-C by ~65% and Lp(a) by ~26%. Patients who achieved greater Lp(a) reduction demonstrated significant decreases in arterial wall FDG uptake — a validated surrogate for active vascular inflammation — while patients with minimal Lp(a) lowering did not. The relationship between magnitude of Lp(a) lowering and arterial wall inflammation reduction was dose-dependent, providing mechanistic evidence that Lp(a)‘s vascular effects are partially mediated through inflammation.

This study is notable for providing mechanistic imaging evidence linking Lp(a) reduction to measurable arterial wall benefit — rather than just treating Lp(a) as a biomarker. The oxidized phospholipid cargo carried by Lp(a) particles drives local arterial wall inflammation, macrophage activation, and foam cell formation; reducing Lp(a) burden appears to attenuate this process in a measurable way.

The 26% Lp(a) reduction achieved by evolocumab is a pharmacological side effect rather than primary mechanism (PCSK9 inhibitors reduce Lp(a) modestly via LDL receptor upregulation). Dedicated Lp(a)-lowering therapies (pelacarsen, olpasiran) achieve 70–90% reductions — the outcome benefit of which is under investigation in cardiovascular outcome trials.

We rate the evidence moderate. A mechanistically important RCT using PET/CT imaging to demonstrate that evolocumab-mediated Lp(a) lowering reduces arterial wall inflammation in proportion to the degree of reduction — providing pathophysiological evidence for Lp(a) as an active mediator rather than passive biomarker.